专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08530430B2 TTK peptides and vaccines including the same 失效
标题翻译： TTK肽和疫苗包括相同
公开(公告)号：US08530430B2
公开(公告)日：2013-09-10
申请号：US13320022
申请日：2010-05-10
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K38/00 , A61K38/08 , A61K39/00 , A61K38/04
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/572 , C07K14/4748
摘要： Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，提供了衍生自引起CTL的TTK基因的表位肽。还提供抗原呈递细胞和靶向这些肽的分离的CTL以及诱导抗原呈递细胞或CTL的方法。本发明还提供含有作为活性成分的衍生自TTK的肽或编码肽的多核苷酸的药物组合物。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用衍生自TTK的肽，编码肽的多核苷酸或呈递肽的抗原呈递细胞，或本发明的药物组合物。

2. 发明申请

US20130064840A1 HJURP PEPTIDES AND VACCINES INCLUDING THE SAME 有权
标题翻译： HJURP肽和疫苗，包括它们
公开(公告)号：US20130064840A1
公开(公告)日：2013-03-14
申请号：US13583195
申请日：2011-03-10
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K39/00 , C12N15/11 , C12N5/0783 , C12N15/63 , C12N15/85 , C12N5/0784 , C07K16/00 , C07K7/06 , A61P35/00
CPC分类号： C07K14/4748 , A61K35/12 , A61K38/00 , A61K39/00 , C07K7/06 , C07K16/18
摘要： Isolated peptides derived from SEQ ID NO: 50 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids sequences substituted, deleted, added or inserted, provided such modified versions retain the requisite cytotoxic T cell inducibility of the original sequence. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, AML, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophagus cancer, Diffused-type gastric cancer, liver cancer, NSCLC, lymphoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal carcinoma, SCLC, soft tissue tumor and testicular tumor.
摘要翻译：衍生自SEQ ID NO：50的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞（CTL）的片段，因此适用于癌症免疫治疗的上下文，更具体地，本文描述了癌症疫苗。本发明的肽包括上述氨基酸序列及其修饰形式，其中一个，两个或几个氨基酸序列被取代，缺失，添加或插入，只要这些修饰形式保留原始序列的必需细胞毒性T细胞诱导性。还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物，物质和/或组合物。本发明的肽，核酸，药物，物质和组合物特别用于治疗癌症和肿瘤，包括例如AML，膀胱癌，乳腺癌，宫颈癌，胆管细胞癌，CML，结肠直肠癌，食管癌，扩散型胃癌，肝癌，NSCLC，淋巴瘤，骨肉瘤，卵巢癌，胰腺癌，前列腺癌，肾癌，SCLC，软组织肿瘤和睾丸肿瘤。

3. 发明申请

US20110243973A1 HIG2 AND URLC10 EPITOPE PEPTIDE AND VACCINES CONTAINING THE SAME 有权
标题翻译： HIG2和URLC10 EPITOPE肽和含有它的疫苗
公开(公告)号：US20110243973A1
公开(公告)日：2011-10-06
申请号：US13059618
申请日：2009-08-14
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K39/00 , C12N15/85 , C12N5/0783 , C12N5/078 , A61P35/00 , A61P37/04
CPC分类号： A61K39/0011 , A61K38/00 , C07K14/7051
摘要： The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.
摘要翻译：本发明提供了含有一种或多种具有SEQ ID NO：1或2的氨基酸序列的肽的一种或多种肽或一种或多种编码用于治疗和/或预防受试者的癌症的肽的多核苷酸的药剂或组合物其HLA-A抗原为HLA-A0206。此外，本发明提供使用这些肽，多核苷酸或药剂诱导CTL和抗原呈递细胞的方法。

4. 发明申请

US20110200626A1 IQGAP3 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME 审中-公开
标题翻译： IQGAP3抗生素肽和含有其的疫苗
公开(公告)号：US20110200626A1
公开(公告)日：2011-08-18
申请号：US12997517
申请日：2009-06-10
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： A61K39/00 , C12N15/87 , C12N5/0783 , C07K7/06 , C12N5/071 , A61K38/08 , C07H21/00 , A61K31/7088 , A61P35/00 , A61P37/04
CPC分类号： C07K14/4722 , A61K39/0011 , C07K7/06 , C07K14/4706
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from IQGAP3 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 or HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the IQGAP3 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the IQGAP3 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, renal, esophageal, gastric, lung, breast, bladder and pancreatic cancer.
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，本发明描述衍生自引起CTL的IQGAP3的表位肽。本发明还提供了特异性识别用肽脉冲的HLA-A24或HLA-A02阳性靶细胞的已建立的CTL。还提供了呈递任何肽的抗原呈递细胞和外来体以及诱导抗原呈递细胞的方法。本发明还提供含有IQGAP3多肽或其编码的多核苷酸以及作为活性成分的外来体和抗原呈递细胞的药剂。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用 IQGAP3多肽，编码多肽的多核苷酸，呈递多肽的外来体或抗原呈递细胞，或本发明的药剂。要靶向的癌症包括但不限于肾，食管，胃，肺，乳腺，膀胱和胰腺癌。

5. 发明申请

US20100040641A1 PEPTIDE VACCINES FOR CANCERS EXPRESSING TUMOR-ASSOCIATED ANTIGENS 有权
标题翻译：用于表达肿瘤相关抗原的癌症的肽疫苗
公开(公告)号：US20100040641A1
公开(公告)日：2010-02-18
申请号：US12542638
申请日：2009-08-17
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K39/00 , C07K7/08 , A61K38/10 , A61K31/7088 , C12N5/02 , C12N5/00 , G01N33/566
CPC分类号： C07K4/12 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/572 , C07K7/06 , C07K14/47 , G01N2500/00
摘要： The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.
摘要翻译：本发明提供了具有SEQ ID NO：19,22,30,34,344,358,41,44,46,48,78,376,49,48,78,376,479,48和78的氨基酸序列的肽。 110,111,387,112,394,114,116,117,121,345,133,135,137,426,143,147,148,149,150,152,153,154,156,160,161， 162,163,166,174,178,186,194,196,202,210,213,214,217,223,227,228,233,254,271,272或288以及具有上述的肽的肽，提供其中1,2或几个（例如，至多5个）氨基酸被取代，缺失或添加的上述氨基酸序列，条件是肽具有细胞毒性T细胞诱导性。本发明还提供用于治疗或预防与CDH3，EPHA4，ECT2，HIG2，INHBB，KIF20A，KNTC2，TTK和/或URLC10的过表达相关的疾病的药物，例如。含有这些肽中的一种或多种的活性成分的癌症。本发明的肽可作为疫苗进一步发挥作用。

6. 发明授权

US09119800B2 HIG2 and URLC10 epitope peptide and vaccines containing the same 有权
标题翻译： HIG2和URLC10表位肽和含有它们的疫苗
公开(公告)号：US09119800B2
公开(公告)日：2015-09-01
申请号：US13059618
申请日：2009-08-14
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K39/385 , A61K39/00 , C07K14/725 , A61K38/00
CPC分类号： A61K39/0011 , A61K38/00 , C07K14/7051
摘要： The present invention provides a pharmaceutical agent or composition containing one or more peptides having the amino acid sequence of SEQ ID NO: 1 or 2, or one or more polynucleotides encoding such a peptide formulated for the treatment and/or prevention of cancer in a subject whose HLA-A antigen is HLA-A0206. Furthermore, the present invention provides a method of inducing CTL and antigen-presenting cells using such peptides, polynucleotides or pharmaceutical agents.
摘要翻译：本发明提供了含有一种或多种具有SEQ ID NO：1或2的氨基酸序列的肽的一种或多种肽或一种或多种编码用于治疗和/或预防受试者的癌症的肽的多核苷酸的药剂或组合物其HLA-A抗原为HLA-A0206。此外，本发明提供使用这些肽，多核苷酸或药剂诱导CTL和抗原呈递细胞的方法。

7. 发明授权

US08697631B2 TMEM22 peptides and vaccines including the same 失效
标题翻译： TMEM22肽和疫苗包括它们
公开(公告)号：US08697631B2
公开(公告)日：2014-04-15
申请号：US13515656
申请日：2010-12-13
申请人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
发明人： Yusuke Nakamura , Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura , Tomohisa Watanabe
IPC分类号： C07K7/06 , A61K38/08 , G01N33/53
CPC分类号： C07K7/06 , A61K39/00 , A61K39/0011 , A61K2039/57 , C07K14/705
摘要： Isolated peptides composed of the amino acid sequence of SEQ ID NO: 33 or fragments thereof that bind to HLA antigens and have cytotoxic T lymphocyte (CTL) inducibility and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical agents, substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors.
摘要翻译：描述了由SEQ ID NO：33的氨基酸序列组成的分离肽或其与HLA抗原结合并具有细胞毒性T淋巴细胞（CTL）诱导性的因此适合用于癌症免疫治疗，特别是癌症疫苗的上下文中的其片段这里。本发明进一步提供了肽，其包括前述肽或片段的一个，两个或几个氨基酸插入，取代或添加，但仍保留所需的细胞毒性T细胞诱导性。还提供了编码任何上述肽的核酸以及包含上述肽或核酸中任何一种的药物，物质和组合物。本发明的肽，核酸，药物，物质和组合物在癌症和肿瘤的治疗中具有特别的用途。

8. 发明授权

US08674069B2 MELK epitope peptides and vaccines containing the same 有权
标题翻译： MELK表位肽和含有它们的疫苗
公开(公告)号：US08674069B2
公开(公告)日：2014-03-18
申请号：US13056598
申请日：2009-07-30
申请人： Takuya Tsunoda , Ryuji Ohsawa
发明人： Takuya Tsunoda , Ryuji Ohsawa
IPC分类号： C07K5/00
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K7/06 , C07K14/4747 , C12N5/0638 , C12N9/12 , C12N2502/11 , C12N2510/00 , C12Y207/10002 , C12Y207/11001
摘要： According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
摘要翻译：根据本发明，具有SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽被证明具有细胞毒性T淋巴细胞（CTL）诱导性。因此，本发明提供了具有选自SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽。肽可以包括一个，两个或几个氨基酸取代，缺失，插入或添加，只要其CTL诱导性得以保留即可。此外，本发明提供了用于治疗和/或预防癌症的药物和/或预防其术后复发，其含有任何这些肽。本发明的药剂包括疫苗。

9. 发明申请

US20110212115A1 MELK EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME 有权
标题翻译： MELK EPITOPE PEPTIDES和含有该胶原蛋白的疫苗
公开(公告)号：US20110212115A1
公开(公告)日：2011-09-01
申请号：US13056598
申请日：2009-07-30
申请人： Takuya Tsunoda , Ryuji Ohsawa
发明人： Takuya Tsunoda , Ryuji Ohsawa
IPC分类号： A61K39/00 , C12N5/078 , C12N15/63 , C07H21/00 , C07K7/06 , C12N5/071 , A61K31/7088 , A61K38/08 , A61K35/12 , A61P37/04 , A61P35/00 , A61P35/02
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K2039/5158 , C07K7/06 , C07K14/4747 , C12N5/0638 , C12N9/12 , C12N2502/11 , C12N2510/00 , C12Y207/10002 , C12Y207/11001
摘要： According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.
摘要翻译：根据本发明，具有SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽被证明具有细胞毒性T淋巴细胞（CTL）诱导性。因此，本发明提供了具有选自SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽。肽可以包括一个，两个或几个氨基酸取代，缺失，插入或添加，只要其CTL诱导性得以保留即可。此外，本发明提供了用于治疗和/或预防癌症的药物和/或预防其术后复发，其含有任何这些肽。本发明的药剂包括疫苗。

10. 发明授权

US09387238B2 CDCA1 epitope peptides and vaccines containing the same 有权
标题翻译： CDCA1表位肽和含有它们的疫苗
公开(公告)号：US09387238B2
公开(公告)日：2016-07-12
申请号：US12999051
申请日：2009-06-18
申请人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
发明人： Takuya Tsunoda , Ryuji Ohsawa , Sachiko Yoshimura
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C07K14/74
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K2039/5154 , A61K2039/53 , A61K2039/572 , A61K2039/575 , C07K14/47 , C12N5/0638
摘要： Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the CDCA1 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the CDCA1 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, breast cancer, bladder cancer, esophageal cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
摘要翻译：本文描述了针对癌症的肽疫苗。特别地，本发明描述了衍生自引起CTL的CDCA1的表位肽。本发明还提供了特异性识别用肽脉冲的HLA-A24阳性靶细胞的已建立的CTL。还提供了呈递任何肽的抗原呈递细胞和外来体以及诱导抗原呈递细胞的方法。本发明还提供含有CDCA1多肽或其编码多核苷酸以及作为活性成分的外来体和抗原呈递细胞的药剂。此外，本发明提供了治疗和/或预防（即预防）癌症（肿瘤）和/或预防其术后复发的方法，以及诱导CTL的方法，诱导抗肿瘤免疫的方法，使用 CDCA1多肽，编码多肽的多核苷酸，呈递多肽的外来体或抗原呈递细胞，或本发明的药剂。要靶向的癌症包括但不限于乳腺癌，膀胱癌，食管癌，小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式